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ABSTRACT Among the many genes involved in the metabolism of therapeutic drugs, human arylamine
N-acetyltransferases (NATs) genes have been extensively studied, due to their medical importance
both in pharmacogenetics and disease epidemiology. One member of this small gene family, NAT2,
is established as the locus of the classic human acetylation polymorphism in drug metabolism. Current
hypotheses hold that selective processes favoring haplotypes conferring lower NAT2 activity have been
operating in modern humans’ recent history as an adaptation to local chemical and dietary environments.
To shed new light on such hypotheses, we investigated the genetic diversity of the three members of the
NAT gene family in seven hominid species, including modern humans, Neanderthals and Denisovans. Little
polymorphism sharing was found among hominids, yet all species displayed high NAT diversity, but dis-
tributed in an opposite fashion in chimpanzees and bonobos (Pan genus) compared to modern humans, with
higher diversity in Pan species at NAT1 and lower at NAT2, while the reverse is observed in humans. This
pattern was also reflected in the results returned by selective neutrality tests, which suggest, in agreement
with the predicted functional impact of mutations detected in non-human primates, stronger directional
selection, presumably purifying selection, at NAT1 in modern humans, and at NAT2 in chimpanzees. Over-
all, the results point to the evolution of divergent functions of these highly homologous genes in the
different primate species, possibly related to their specific chemical/dietary environment (exposome) and
we hypothesize that this is likely linked to the emergence of controlled fire use in the human lineage.
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Hominid species, the so-called “great apes”, share a recent common
history that makes the genomic diversity of our closest relatives highly
informative in evolutionary studies on our own species and more
broadly on all great apes. This potential to answer evolutionary ques-
tions regarding all hominid species, including our own, is extensively
exploited, and notably so in the last half decade thanks to the accelera-
ted pace at which whole genome sequences are generated (Kuhlwilm
et al. 2016). As foreseen by Olson and Varki (2003), analyzing genetic
and genomic diversity in the great apes is also providing novel in-
sights of medical interest (e.g., (Enard et al. 2002; Bergfeld et al. 2017;
Solis-Moruno et al. 2017). Indeed, physiological differences between
species, whether they emerged through demographic processes or
as adaptive responses might offer insights into present-day ques-
tions regarding human health and disease (Olson and Varki 2003;
O’Bleness et al. 2012).
Arylamine N-acetyltransferases (NATs) genes are members of a
small multigene family coding for enzymes that biotransform numer-
ous compounds. In humans, its two functional members, NAT1 and
NAT2, show differences in expression patterns and substrate speci-
ficity, while the third member (NATP) is a pseudogene. While the
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NAT2 isoenzyme has a major role in the metabolism of xenobiotics,
including therapeutic drugs and carcinogens, growing evidence sup-
ports an additional role for NAT1 in physiological processes (notably
folate and methionine metabolism) and cancer cell biology. The three
NAT genes reside in a 200 Kb region on the short arm of chromosome
8, and each of the two functional genes has a single, uninterrupted,
870 bp-long coding exon that produces a protein of 290 amino acids
(Blömeke and Lichter 2018; Sim and Laurieri 2018). Phylogenetic
analyses of NAT sequences point to multiple episodes of NAT gene
duplication or gene loss during vertebrate evolution (Sabbagh et al.
2013). However, in Simiiformes (monkeys and apes, including
humans) the evidence suggests the occurrence of a single duplica-
tion event prior to their divergence, leading to the NAT1 and NAT2
paralogs, whereas a subsequent duplication of NAT2, which probably
occurred in the common ancestor to Catarrhini (African and Eurasian
monkeys and apes, including humans), gave rise to the NATP pseu-
dogene. Nucleotide sequence identity between the three NAT paral-
ogs in humans is high: there is 81% homology between NAT1 and
NAT2 coding exons, and 79% with the NATP pseudogene, while
protein sequence identity between the two NAT enzymes is at 87%
(Sabbagh et al. 2013). Homology between orthologous nucleotide
sequences of humans, chimpanzees and gorillas is also high, about
98–99% for NAT1 and NAT2, and 96–97% forNATP, according to the
human (GRCh37/hg19, (Lander et al. 2001)), chimpanzee (panTro4,
(The Chimpanzee Sequencing and Analysis Consortium 2005)) and
gorilla (gorGor4, (Scally et al. 2012)) reference genomes, with no clear
distinction between these three great ape species. Indeed, identity at
NAT1 between the human and chimpanzee reference sequences
is 98.5%, compared to 99% between human and gorilla, and 98.5%
between chimpanzee and gorilla; at NAT2 it is 98.6% between human
and chimpanzee, 98.8% between human and gorilla, and 98.9%
between chimpanzee and gorilla; and at NATP it is 96.8% between
human and chimpanzee, 95.8% between human and gorilla, and 96.1%
between chimpanzee and gorilla. These occurrences of apparent in-
complete lineage sorting (although based on very slight differences)
are not surprising since it is estimated that about a third of the gorilla
genome is more similar to that of humans or chimpanzees than the
human and chimpanzee genomes are to each other (Scally et al. 2012;
Kronenberg et al. 2018). It highlights the complex speciation history
of great apes, which possibly included several admixture events, such
as those recently evidenced between bonobos and the ancestors of
Central and Eastern chimpanzees (de Manuel et al. 2016).
Due to their involvement in inter-individual variation in response to
therapeutic treatments, the molecular diversity ofNAT genes in human
populations has been intensively studied (Sabbagh et al. 2018). In par-
ticular, the NAT2 encoded enzyme, mainly expressed in the liver, small
intestine and colon, is involved in the metabolic breakdown of several
clinically relevant compounds (Hein 2002), including isoniazid, a first-
line antibiotic included in anti-tuberculosis therapies since the 1950s
(Zumla et al. 2013). Yet, it is safe to assume that none of these com-
pounds have had any evolutionary impact on human NAT2 evolution.
The single coding exon of NAT2 is highly polymorphic in humans,
and it has been shown that the efficacy and/or toxicity of several
clinically important drugs are associated with variation in enzymatic
activity conferred by different NAT2 variants (Meyer 2004; Agundez
2008a; McDonagh et al. 2014). This, together with the involvement of
the enzyme in the detoxification (N, O or N,O-acetylation) of numer-
ous carcinogens, motivated numerous studies on the evolution of the
diversity ofNAT2 in human populations. Current hypotheses hold that
geographically- or culturally-restricted selective processes favoring one
or several haplotypes conferring lower NAT2 activity (as adaptations to
specific chemical environments or dietary habits) have been operating
in the recent history of human populations (Patin et al. 2006a; Patin
et al. 2006b; Fuselli et al. 2007; Luca et al. 2008; Magalon et al. 2008;
Sabbagh et al. 2008; Mortensen et al. 2011; Sabbagh et al. 2011; Patillon
et al. 2014; Podgorná et al. 2015; Valente et al. 2015; Bisso-Machado
et al. 2016); see also (Sabbagh et al. 2018) for a review). Interestingly,
the discovery of a strong association of decreased insulin sensitivity
with a non-synonymous polymorphism inNAT2 (Knowles et al. 2016)
brings indirect support to the hypothesis of dietary-linked selective
pressures exerted on the evolution of this gene. NAT1 is also involved
in N-acetylation reactions of numerous compounds, and it is mainly
expressed in the liver. Moreover, as shown in the AceView browser
(Thierry-Mieg and Thierry-Mieg 2006), it is also expressed in kidneys,
lung, and blood cells, particularly in humans, and less so in chimpan-
zees. However, in contrast to NAT2, NAT1 is substantially less poly-
morphic in humans, and it is currently held that the accumulation of
molecular variation in the NAT1 coding exon, in particular non-
synonymous variation, has been hampered by relatively strong pu-
rifying selection acting on the gene (Patin et al. 2006a; Mortensen
et al. 2011; Sabbagh et al. 2018). NATP, the third identified member
of this family of genes in the human genome bears several loss-of-
function mutations and transcriptome studies indicate that it is barely
if ever transcribed (as shown in the EBI Gene Expression Atlas, entry
ENSG00000253937 at www.ebi.ac.uk/gxa/home).
One approach to examine hypotheses of recent adaptation in
acetylation activity in humans is to investigate the diversity of NAT
genes in humans’ closest relatives. To this aim, we Sanger sequenced
the three members of the NAT gene family in 84 great ape DNA sam-
ples, including 68 chimpanzees of the Pan troglodytes verus sub-species
(Western chimpanzees). We completed this dataset with 231 NAT
sequence genotypes produced with NextGen technology by the Great
Ape Genome Project (GAGP) (Prado-Martinez et al. 2013). We also
examined NAT sequence variation in reference genomes of ancient
hominins (i.e., Homo sapiens from Ust’-Ishim, Neanderthal and
Denisova). Similarly to humans, we found high levels of nucleotide
and haplotype diversity in non-human primates, but distributed dif-
ferently in Pan, such that diversity is higher at NAT1 and lower at
NAT2, whereas the opposite is observed in humans. Hence we hy-
pothesize that the highly homologousNAT1 andNAT2 genes evolved
some divergence in functionality between species in the course of
hominid history, and we discuss this hypothesis in relation to changes
in the chemical or dietary environment, i.e., the exposome (Wild
2012) in which humans and chimpanzees have evolved.
MATERIALS AND METHODS
Great ape DNA samples
Eighty-fourDNAsamples of great apeswere analyzed in this study. These
comprised DNA from 68 Pan troglodytes verus (Western chimpanzee)
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individuals, one P. t. troglodytes (Central chimpanzee) female, one
P. t. schweinfurthii (Eastern chimpanzee) female, one P. paniscus
(bonobo) male, five Gorilla gorilla and eight Pongo abelii (Sumatran
orangutan) individuals. Among the 68 P. t. verus samples, 40 were
from members of the Biomedical Primate Research Centre (BPRC)
colony, 26 from the Center for Academic Research and Training in
Anthropogeny (CARTA) and two from the Basel zoo (Supplementary
Figure S1). These samples and their corresponding collections are
described in Supplementary File S1.
Sanger sequencing of NAT genes
We sequenced the three segments in the NAT region that include the
single coding exons of NAT1 and NAT2 and the homologous DNA
stretch of NATP in the 84 DNA samples of great apes available for this
study. Supplementary Table S1 lists the primers used in this study both
for PCR amplification and forward and reverse sequencing of each
of the three NAT loci in great apes. PCR conditions are provided in
Supplementary File S1. Sanger sequencing was outsourced to Retrogen
(San Diego, California, USA) and Macrogen (Seoul, South Korea).
Supplementary Table S2 lists the available information on all non-
human samples considered in this study, including those retrieved
from the GAGP (see below).
Alignment of NAT sequences
All NAT sequences obtained were aligned on the homologs from the
reference or draft reference assemblies of Homo sapiens (GRCh37/hg19,
February 2009), Pan troglodytes verus (panTro4, February 2011), Pan
paniscus (panPan1, May 2012), Gorilla gorilla gorilla (gorGor4,
December 2014, as well as gorGor3 for verification, since these two
reference sequences are not identical) and Pongo pygmaeus abelii
(ponAbe2, July 2007), respectively, all downloaded from the UCSC
Genome Browser (Kent et al. 2002, genome.ucsc.edu). Alignment was
performed blind of the known relationships between individuals.
Retrieval of NAT sequences or polymorphic positions
from public repositories
For comparison purposes, we retrieved NAT genotypes from the pub-
lished unphased genomes of 79 great apes generated in the GAGP by
NGS (Prado-Martinez et al. 2013), namely from 25 chimpanzees (includ-
ing a hybrid P. t. verus/troglodytes individual), 13 bonobos, 31 gorillas
and 10 orangutans. Two individuals, Harriet (P. t. schweinfurthii) and
Boscoe (P. t. verus, Supplementary Figure S1), were in common in the
GAGP andCARTA datasets, thus allowing a control of Sanger andNGS
sequencing results. We extracted the relevant part of the available VCF
files. Further details are provided in Supplementary File S1. All detected
polymorphic positions in the Sanger sequenced samples of this study
and retrieved from the GAGP VCF files are detailed in Supplementary
Tables S3, S4 and S5, for NAT1, NAT2 and NATP, respectively.
To allow comparison of segregating sites at the NAT genes among
all hominids (i.e., all great apes, including humans), we recorded all human
polymorphisms reported by the consensus gene nomenclature of human
NAT alleles (http://nat.mbg.duth.gr/, accessed in August 2015), com-
plemented with haplotype data from 1000 Genomes Phase 1 (The
Genomes Project Consortium 2012) and published data (Patin et al.
2006a; Sabbagh et al. 2008; Mortensen et al. 2011; Podgorná et al.
2015). These are also reported in Supplementary Tables S3, S4 and S5.
Inference of NAT haplotypes in the genus Pan
Diploid haplotypes were inferred for all Pan individuals (but not for
the other great ape samples, see Supplementary File S1) using PHASE
version 2.1.1 (Stephens et al. 2001; Stephens and Scheet 2005). The
program uses a Bayesian statistical method based on an approximate
coalescent model for reconstructing haplotypes from genotype data.
PHASE implements a recombination method (the –MR option), which
allows specifying the relative physical location of each SNP and
accounts for the decay in linkage disequilibrium with distance.
Constitution of two samples of Pan troglodytes verus
unrelated individuals
We considered separately two samples of unrelated individuals from
the Western (P. t. verus) chimpanzee sub-species, BPRC and San
Diego (Supplementary File S1), notably due to significant differenti-
ation between these two samples at the NATP pseudogene (Supple-
mentary Table S6, see results).
NAT haplotypes in humans
A dataset of NAT haplotypes’ frequency distributions in human
population samples was assembled with published NAT sequences
of same length as those of Pan, obtained through a comprehensive
literature search at the time of the study. Only populations repre-
sented by samples including at least 15 individuals (30 chromosomes)
were considered. We thus used published data samples fromMortensen
et al. (2011) and from Sabbagh et al. (2008). We also extracted NAT1,
NAT2 and NATP phased genotypes from the 1000 Genomes Phase
1 dataset (The Genomes Project Consortium 2012), see Supplementary
File S1. In total, the human dataset consists of 20, 18 and 18 samples
of unrelated individuals, from human populations distributed on four
continents (Sub-Saharan Africa, Europe, East Asia and America), for
NAT1, NAT2 and NATP, respectively (Supplementary Table S7).
NAT polymorphisms in ancient genomes of hominins
Variant calls in the homologous NAT sequences of ancient genomes
of the genus Homo, namely Neanderthal, Altai and the composite
genome of three individuals from Vindija, (Green et al. 2010; Prüfer
et al. 2014), Denisova (Meyer et al. 2012), and those from the most
ancient modern human sequenced genome, Ust’-Ishim (Fu et al.
2014), were examined in both the UCSC Genome Browser (https://
genome.ucsc.edu/) and the ancient genome browser at the Max Planck
Institute for Evolutionary Anthropology (http://www.eva.mpg.de/
neandertal/index.html), the latter including the recently published
high-coverage Vindija Neanderthal genome (Prüfer et al. 2017). For
each of the two functional genes, we screened 2 Kb of the reference
human genome sequence (Hg19/GRCh37) encompassing the coding
exon (positions 18’079’000 to 18’081’000 forNAT1, and 18’257’000 to
18’259’000 for NAT2). For the NATP pseudogene, we screened 2 Kb
of homologous sequence (18’227’600 to 18’229’600).
Analysis of diversity of NAT genes in the genus Pan and
comparison with humans and other great apes
Frequency distributions of NAT haplotypes in the Pan and human
population samples were used to test for possible deviations fromHardy
Weinberg equilibrium, to estimate expected heterozygosity, (h, equiva-
lent to Nei’s gene diversity, (Nei 1987)) and nucleotide diversity (p), to
estimate levels of population differentiation (FST statistics), and to test
for possible departure from selective neutrality and demographic equi-
librium (Ewens-Watterson homozygosity test, Tajima’sD test and Fu’sFS
test,), with the program Arlequin ver. 3.5 (Excoffier and Lischer 2010).
Each of these three latter tests relies on different summaries of diversity
(homozygosity for the Ewens-Watterson test, number of polymorphic
sites and nucleotide diversity for Tajima’s D, and number of different
Volume 9 July 2019 | Diversity in Hominid NAT genes | 2201
haplotypes and nucleotide diversity for Fu’s Fs), and only Tajima’s D
and Fu’s Fs tests explicitly account for the mutational events distin-
guishing haplotypes. Statistical significance was assessed by generating
100’000 random samples under the null conditions of no selection and
constant population size. For all tests that revealed at least one signif-
icant departure from the null hypothesis in one population (species,
sub-species, or collection in the case of P. t. verus), the Holm correction
method implemented in R (R Core Team 2013) was applied to control
for type I error rate (Holm 1979), so as to obtain adjusted P-values.
Arlequin was also used to infer population pairwiseFST values (between
species, sub-species, or collections) under the AMOVA framework, and
their statistical significance was assessed with 100’000 permutations.
The parameters used to estimateFST values were obtained withMEGA
ver. 7 (Kumar et al. 2016). These parameters are: the molecular model
(Tamura’s distance for all three NAT loci), the gamma parameter (no
gamma correction forNAT1 and NAT2, gamma = 0.05 for NATP) and
the transition to transversion ratio (2.67, 2.0 and 2.5 for NAT1, NAT2
and NATP, respectively). The program Network ver. 5.0 (Bandelt
et al. 1999) was used to construct median-joining networks of NAT
haplotypes in Pan.
Prediction of functional impact of specific mutations in
Pan haplotypes at the NAT1 and NAT2 loci
Phenotypic predictions of the functional impact of specific mutations
in Pan NAT1 and NAT2 haplotypes were performed with three online
software tools (analysis done in May 2017): PolyPhen (Adzhubei et al.
2010), SIFT (Sim et al. 2012) and the PANTHER cSNP Scoring tool
(Tang and Thomas 2016). These three tools are able to predict the effect
of a single nonsynonymous substitution on a protein sequence (Sup-
plementary File S1). To investigate and compare the results returned
by these methods, we first applied the three tools on human haplo-
types of known phenotypes (Supplementary File S1). For the analysis
of Pan haplotypes, we ran all three prediction tools with the default
options, searching the UniProtKB/TrEMBL protein database (release
2010_09) with SIFT, and specifying Pan troglodytes as reference
organism in PANTHER cSNP Scoring.
Data availability
File S1 contains detailed descriptions of the protocols used for DNA
amplification, PCR product purification and sequencing of great ape
samples, retrieval of unphased NAT polymorphic positions from the
Great Ape Genome Project (GAGP), inference of Pan NAT haplotypes,
and retrieval of phased humanNAT haplotypes from the 1000 Genomes
Project. Table S1 lists the PCR and sequencing primers used for Sanger
sequencing of NAT genes in non-human great ape DNA samples, and
available information on these samples is provided in Table S2. Hominid
polymorphic positions detected inNAT1,NAT2, andNATP are listed in
Tables S3, S4, and S5, respectively. Table S6 reports estimates of differ-
entiation levels between Pan (sub-)species. Table S7 lists the human
population samples included in the modern human dataset, with
associated diversity estimates and results of Hardy-Weinberg equi-
librium tests. Supplementary information on results is also provided
in File S1. All supplementary material has been uploaded to figshare.
The 247 NAT sequenced genotypes obtained in this study are avail-
able in GenBank with accession numbers MK244999-MK245288 and
MK245291-MK245459. Supplemental material available at FigShare:
https://doi.org/10.25387/g3.7928192.
RESULTS
In this study, we Sanger sequenced approximately 1 Kb of homol-
ogous sequence in each of the three members of the arylamine
N-acetyltransferase (NAT) gene family, NAT1, NAT2 and the NATP
pseudogene, in 84 great ape samples, of which 68 are chimpanzees of
the Pan troglodytes verus sub-species. Out of the 84 DNA samples of
great apes available, we obtained 248 NAT genotypes (83, 81 and
83 NAT1, NAT2 and NATP genotypes, respectively, Supplementary
File S1). We extended our dataset with 231 NAT genotypes from
79 individuals belonging to six great ape (sub-)species retrieved
from the GAGP (Prado-Martinez et al. 2013). As reported in Tables 1
and 2, the total dataset assembled for analysis thus included 93 geno-
types from four Pan troglodytes (common chimpanzee) sub-species for
NAT1 and NAT2 (96 for NATP), 14 genotypes from Pan paniscus
(bonobo) for each of the 3 NAT genes, 35 genotypes from two Gorilla
species for NAT2 and NATP (36 for NAT1), and 17 genotypes from
two Pongo (orangutan) species for NAT1 and NAT2 (18 for NATP).
For comparative analysis purposes, we also assembled a human NAT
dataset totalizing 1’159 to 1’240 unrelated individuals from 18 to
20 populations distributed on four continents.
In spite of the high level of known homology between the three
NAT genes, approximately 8% nucleotide positions in NAT1 (76 out
of 903 bp), 10% in NAT2 (117 out of 1’115 bp), and 15% in NATP
(151 out of 1’002 bp) are segregating positions in hominids, that were
found to either be divergent between species, polymorphic within a
species, or both (Supplementary Tables S3, S4, and S5). Among them,
21 (28%) substitutions in NAT1, 38 (32%) in NAT2, and 77 (51%) in
NATP correspond to inter-species divergence.
NAT polymorphisms in hominids and polymorphism
sharing among species
Despite the high numbers of segregating sites detected at the three
NAT genes in hominids, little polymorphism was found to be shared
between humans, gorillas, orangutans and Pan: two SNPs at NAT1,
four at NAT2 and six at the NATP pseudogene (Table 1).
No polymorphic position was found shared between the genus Pan
and the other great ape species at the NAT1 gene (Table 1 and Supple-
mentary Table S3). Nonetheless, the proportion of non-synonymous
SNPs in Pan (60%) is similar to that observed in humans (59%) and
orangutans (56%), while it is lower in gorillas (25%).
Humans and orangutans were found to share two NAT1 SNPs,
i.e., non-synonymous A/G at human cds position 445 (rs4987076)
and synonymous G/A at 459 (rs4986990), the former being also ob-
served in gorillas. These two polymorphisms, found at low frequen-
cies in humans today, along with a third one not observed in gorillas
or orangutans (non-synonymous 640 G/T, rs4986783), were never-
theless detected in the ancient genome of 45’000 years old Homo
sapiens from Ust’-Ishim, and were found to diverge between Nean-
derthals and Denisova (Table 1 and Supplementary Table S8). Inter-
estingly, ancient Neanderthal genomes apparently carry the same allele
(A) as Pan at rs4987076 whereas the alternative allele (G) was found
for Denisova, and the opposite pattern is observed at rs4986990 (both
Pan and Denisova carry G, while ancient Neanderthal genomes carry
A). Thus, both the 445 A/G (rs4987076) and the 459 G/A (rs4986990)
polymorphisms could potentially either pre-date the divergence among
hominids or represent a case of independent parallel mutation(s) in
hominins and in other great ape lineages. In turn, at position 640 G/T
(rs4986783), all great apes and Neanderthals were found to carry G,
whereas the alternative allele (T) was only observed in Denisova. In
humans today, the derived alleles (respectively A, A and G) at these
three SNPs (respectively, rs4987076, rs4986990 and rs4986783) char-
acterize human haplotypes NAT111A and NAT111B. A previous
study estimated that the coalescence of NAT111A with other major
human NAT1 haplotypes (NAT13, NAT14, and NAT110) dates
2202 | C. Vangenot et al.
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back to 2 million years ago, leading the authors to suggest that some
NAT1 diversity in the genome of modern humans may have persisted
from a structured ancestral population (Patin et al. 2006a). Since
SNPs 445 A/G and 459 G/A are shared between humans and orang-
utans (SNP 445 A/G being also shared with gorillas), their coalescence
times could be even older and likely pre-date the divergence among
hominids. When considered together, the three SNPs define three
major combinations in hominids, GGT, AGG, and AAG. The most
frequent combination in humans, GGT, which characterizes most
human haplotypes (except those of the NAT111 series and NAT130),
was not observed in the other great apes. Instead, all haplotypes in
chimpanzees and bonobos carry the AGG combination, which has an
estimated frequency of 70% in gorillas, and at least 55% in orangu-
tans, but has not been reported so far in human populations. Such
observations could suggest that the AGG haplotype was present in the
ancestors of hominids (the reference sequences of rhesus (Macaca
mulatta) and cynomolgus (M. fascicularis) macaques, rheMac8 and
macFas5, also carry the AGG combination), and was lost at some
point in the human lineage, possibly after the divergence from Deni-
sova and Neanderthal. Indeed, Denisova’s ancient genome is defined
as GGT, while the Altai and Vindija Neanderthal genomes are re-
ported with the AAG combination, and the genome of 45’000 years
old Homo sapiens from Ust’-Ishim is heterozygous at the three
positions (Supplementary Table S8). Nowadays, the human reference
haplotype NAT14, together with other haplotypes carrying GGT at
the three SNPs (e.g., human NAT13 and NAT110), have an average
cumulated frequency of 95% in all human populations studied so
far, whereas haplotypes with AAG (the human NAT111 series) are
observed at very low frequencies in populations from Africa, Asia,
Europe and New Guinea (Patin et al. 2006a; Mortensen et al. 2011).
NAT2 stands in sharp contrast with NAT1, mainly because of the
high levels of NAT2 polymorphism in humans (Supplementary Table
S4, 55 polymorphic positions recorded for humans at NAT2, which
represents twice asmany compared toNAT1). The proportion ofNAT2
non-synonymous SNPs in humans (75%) seems higher than that found
in Pan (56%), orangutans (58%), and gorillas (38%).
It is noticeable that among the four NAT2 polymorphisms shared
between hominid species (or five if considering modern humans and
Neanderthals as distinct species), all are shared with humans. Two of
these are non-synonymous polymorphisms in humans shared with
the Pan genus: G/A at human cds position 191 (rs1801279) observed
in bonobos, and C/T at 578 (rs79050330) observed in Western chim-
panzees (Table 1). Humans were also found to share two SNPs with
gorillas: synonymous C/T at 345 (rs45532639) and non-synonymous
A/G at 506 (rs200585149). These shared SNPs are rare polymorphisms
in humans (Sabbagh et al. 2008; The Genomes Project Consortium
2012), with the exception of 191 G/A (rs1801279), the signature
mutation of human haplotypes of the NAT214 series (NAT214A/
B/E/H/L), observed mostly among African populations (Patin et al.
2006a; Mortensen et al. 2011; Podgorná et al. 2015). None of the
polymorphisms detected in orangutans are shared with other great
apes. Remarkably, the common human synonymous C/T SNP at
282 (rs1041983) was found polymorphic in one Neanderthal an-
cient genome (Altai, Supplementary Table S8). This SNP is, up to
now, the sole NAT exonic position recorded as polymorphic in a
non-anatomically modern human ancient genome. Note that due
to an apparent inconsistency between the ancient genome browser
at the Max Planck Institute for Evolutionary Anthropology and
the UCSC genome browser, we could not conclude whether the
NAT2 SNP 803 A/G (rs1208) differentiates the Denisova genome
from Neanderthals and all other hominids (Supplementary Table S8).
This mutation is common in most modern human populations except
in East Asia, and despite being non-synonymous it does not alter the
enzyme’s activity (Zang et al. 2007).
Sequence diversity at the NATP pseudogene in hominids differs
from that of its functional paralogs by the presence of several inser-
tions and deletions (InDels) that could be evidenced in the Sanger
sequenced samples of this study, and most of which mark divergence
between species (Supplementary Table S5). In addition to InDels, high
levels of single nucleotide polymorphisms also characterize this pseu-
dogene in hominids (45 SNPs detected in humans, 13 in gorillas, 19 in
orangutans, and 17 at least in the genus Pan), but similarly to the
functional NAT1 and NAT2 genes, little sharing between species was
found (Table 1). Ancient Homo genomes also reflect the high level of
hominid polymorphism at NATP (Supplementary Table S8). Besides
three modern human SNPs that were also found heterozygous in
the ancient Ust’-Ishim Homo sapiens sample, three positions at least
apparently differ between Neanderthals and Denisova, a proportion
similar to that of NAT1. We also note that an A/G polymorphism is
reported in Denisova (at position 18’228’182) which, according to
our dataset, has not been detected in any other hominid species.
Within the Pan genus, the largest group of genotyped samples in
this study (and in particular the Western chimpanzee sub-species,
Pan troglodytes verus), 40 segregating sites were observed in total for
the three NAT genes. Among these 40 sites, only 15 were found in
Western chimpanzees (Table 2; see also Supplementary File S1, and
Supplementary Tables S3, S4 and S5). We detected 32 polymorphic
positions in common chimpanzees (P. troglodytes), but only five are
shared by all Pan troglodytes sub-species (Table 2).
None of the polymorphic positions shared between all common
chimpanzees is observed in bonobos (P. paniscus). In this latter species,
only five polymorphic sites were identified in the three NAT genes, one
of which (at 18’079’925 in NAT1) is shared withWestern chimpanzees
and the other (at 18’228’659 in NATP) with Central and Eastern chim-
panzees. Six positions were apparently fixed on the derived allele in
bonobos, one of them (at 18’228’285 in NATP) being polymorphic in
common chimpanzees.
NAT haplotypes in Pan
The Arylamine N-acetyltransferase gene nomenclature committee
(Hein et al. 2008) currently lists 28 human NAT1 haplotypes encod-
ing a dozen variant NAT1 proteins, some of which are associated with
lower enzymatic activity than the reference human NAT14 haplo-
type, while the number of documented human NAT2 haplotypes
listed is 108 and the number of encoded variant NAT2 proteins
comes close to 70, about 15 of which are involved in a “slow” acety-
lation phenotype (http://nat.mbg.duth.gr). In humans, as reviewed in
(Sabbagh et al. 2018), frequency distributions of haplotypes encoding
NAT2 proteins are highly variable among populations (see for
instance Figure 2 in (Sabbagh et al. 2018)), whereas for NAT1,
frequency distributions inmost human populations are dominated by
only two major haplotypes (with cumulated frequencies varying be-
tween 85% and 100%), that differ by two SNPs in the 39UTR region
and whose relative phenotypic effect is considered as moderate (hap-
lotype NAT110 probably enhancing protein expression relative to
the most common haplotype, NAT14, (Hein et al. 2018)).
Knowledge of NAT diversity within other great ape species is at
present lacking. We thus inferred haplotypes at the three homolo-
gous NAT genes for individuals belonging to the genus Pan (due to
the small size of available samples, such inference was not possible
for gorillas and orangutans), so as to characterize Pan NAT diversity,
and predict the functional consequences of non-synonymousmutations.
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The PHASE analysis of the 108 Pan genotypes (94 chimpanzees and
14 bonobos) led to the inference of 12 Pan haplotypes for NAT1,
10 for NAT2, and 19 for NATP (Table 3).
We found dissimilar frequency distributions between the threeNAT
genes in all Pan species (Table 4 and Figure 1; haplotype counts in the
total samples including related individuals are provided in Supplemen-
tary Table S9). As reported in Table 4, none of these frequency distri-
butions were found to deviate fromHardy-Weinberg equilibrium, after
correction for multiple testing.
AtNAT1, haplotype frequency distributions in all chimpanzee sub-
species are characterized by a single major haplotype (NAT11 occur-
ring at frequencies between 65% and 80%) along with three to four
other haplotypes at lower frequencies (Table 4 and Figure 1). By
contrast, NAT16 is the more frequent haplotype in bonobos (54%),
followed byNAT11 andNAT112 (25% and 21%, respectively). When
measured by FST fixation indices, which take into consideration the
molecular diversity of haplotypes, significant differentiation was only
found between bonobos and the other Pan (Supplementary Table S6).
On the other hand, it is noteworthy that in bonobos, the two haplo-
types NAT16 and NAT112 observed besides NAT11 differ from it
only by a single synonymous mutation (Table 3 and Supplementary
Figure S2). In other words, 100% of proteins expressed by NAT1 in
bonobos are identical to the product of the NAT11 haplotype pre-
dominant in all chimpanzee sub-species. In turn, most of the other
NAT1 haplotypes detected in these sub-species differ from NAT11
by one non-synonymous change, resulting in the existence of seven
distinct NAT1 proteins: at least four in each of theWestern (P. t. verus),
Central (P. t. troglodytes), and Eastern (P. t. schweinfurthii) sub-species,
and three in the Nigeria-Cameroon (P. t. ellioti) chimpanzees, according
to our observations (Supplementary Table S10).
AtNAT2, a single frequent haplotype is observed in all Pan species,
along with one to three less frequent haplotypes (Table 4 and Figure 1).
In contrast to NAT1, the frequency of the most prevalent NAT2
haplotype is higher (80–92.5%), and it differs between species and
sub-species: it is NAT21 in the Western (P. t. verus), NAT24 in
the Central (P. t. troglodytes) and Eastern (P. t. schweinfurthii), and
NAT26 in the Nigeria-Cameroon (P. t. ellioti) chimpanzee sub-species,
and NAT27 in the bonobos (P. paniscus). Also in contrast to NAT1,
no NAT2 haplotype was found shared between chimpanzees and
bonobos. Thus, unsurprisingly, significant differentiation was found
not only between bonobos and the other Pan, but also between all
chimpanzee sub-species, except between Central (P. t. troglodytes) and
Eastern (P. t. schweinfurthii) chimpanzees (Supplementary Table S6).
On the other hand, although haplotype NAT24 is the predominant
haplotype in Central and Eastern chimpanzees, it only differs by one
synonymous mutation from the most prevalent NAT21 haplotype
in Western (P. t. verus) chimpanzees (Table 3 and Supplementary
Figure S3). This suggests little differentiation between these three
Western, Central, and Eastern sub-species at the level of NAT2 gene
products. Indeed, the 10 NAT2 haplotypes detected in Pan translate
into six distinct NAT2 proteins, of which we observed two in each of
the chimpanzee subspecies, and three in bonobos (Supplementary
Table S10). In fact, both the commonest haplotype in Nigeria-Cameroon
chimpanzees (NAT26 in P. t. ellioti) and all haplotypes in bonobos
differ from most other Pan NAT2 haplotypes by at least one non-
synonymous change.
Finally, the NATP pseudogene haplotypes are more evenly distrib-
uted than those of the two functional genes in all the chimpanzee
sub-species, with two or more frequent NATP haplotypes (Table 4
and Figure 1). By contrast, in bonobos, only two haplotypes were
found, one of which with a frequency of 96% (NATP18), and none is
shared with chimpanzees. However, substantial haplotype sharing
is observed between chimpanzee sub-species, notably for haplotypes
NATP2 and NATP8. Analyses of molecular variance detected a
significant level of genetic differentiation only between bonobos
and all chimpanzees, and among the latter, betweenWestern chim-
panzees (P. t. verus) and the other sub-species (Supplementary
Table S6). A high level of sequence diversity at NATP may explain
these complex results. Indeed, the median-joining network of NATP
haplotypes (Supplementary Figure S4) displays two reticulations and
a few rather divergent haplotypes (e.g., NATP14, NATP15, and
NATP16), which raises the possibility that some Pan haplotypes were
unsampled.
Predicted functional differences among NAT1 and
NAT2 haplotypes in Pan
We chose Pan NAT11 and Pan NAT24, the basal haplotypes in the
median-joining networks of NAT1 and NAT2 haplotypes, respectively
(Supplementary Figures S2 and S3), as reference sequences to predict
the functional impact of NAT mutations in Pan using PolyPhen, SIFT
and PANTHER cSNP Scoring, three online software tools.
Four of the 11 Pan NAT1 haplotypes derived from NAT11 were
predicted to be damaging with more or less confidence (Table 5):
NAT14 and NAT17, each predicted by two tools, and NAT13 and
NAT18 by one tool only. The other seven haplotypes were either
predicted as not damaging or only differ from the others by synon-
ymous mutations. The cumulated frequencies of potentially damag-
ing haplotypes could thus reach the values of 10–13% in Western
(P. t. verus) chimpanzees, 8–10% in Eastern (P. t. schweinfurthii)
and Nigeria-Cameroon (P. t. ellioti) chimpanzees, and up to 20% in
Central (P. t. troglodytes) chimpanzees, at best (Table 4, Figure 1, and
Supplementary Figure S2). If confirmed, these results suggest that a
sizeable proportion of chimpanzees may have a moderately reduced
NAT1 acetylation capacity. Nevertheless, the frequency profiles of
NAT1 in the Pan species and sub-species are characterized by a
majority of haplotypes that are not damaging, and thus translating
into a similar enzymatic activity.
As displayed in the Pan NAT2 network (Supplementary Figure S3),
nine haplotypes derive from the NAT24 basal haplotype, three of
which reaching high frequencies, i.e., NAT21, NAT26, and NAT27
(Table 4, Figure 1 and Supplementary Figure S3). Three low frequency
haplotypes out of the nine stemming from the basal haplotype were
predicted as damaging with high confidence by the three tools: NAT22,
only observed in P. t. verus, and NAT28 and NAT29, the two hap-
lotypes observed only in P. paniscus. Interestingly, the mutations that
define NAT22 and NAT28 both occur at positions that are also
polymorphic in humans (positions 578, rs79050330 and 191, rs1801279,
respectively). The effect of SNP 191 G/A on NAT2 enzymatic activity in
humans is known; it defines the humanNAT214 haplotype series that is
associated with a slow acetylation phenotype (see Supplementary File
S1), which is thus consistent with our prediction results. That of SNP
578 T/C (which is associated in humans with haplotypes NAT25P,
NAT212E, and NAT213B) is unknown. The prediction tools do not
return clear-cut results for the mutations defining NAT26 (derived
from NAT21, and predominant in P. t. ellioti) and NAT27 (derived
from NAT24, and predominant in P. paniscus) (namely A/G at po-
sition 514 and G/A at 145, respectively), predicted as possibly dam-
aging by PANTHER cSNP Scoring only, and with a low confidence.
This suggests that their potential effects are either less damaging
than those of mutations defining NAT22, NAT28, and NAT29
(i.e., rs79050330 C/T at 578, rs1801279 G/A at 191, and SNP A/C at
72), or that they depend on the substrate, as is known for some human
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polymorphisms (Hein et al. 2006) (see Supplementary File S1). In
contrast to Western (P. t. verus) chimpanzees, where the cumulated
frequencies of NAT22, NAT28 and NAT29 are lower than 5%,
they reach 10% in bonobos (Table 4 and Figure 1). If confirmed, our
prediction results could thus indicate that a significant proportion
of bonobos (but a smaller proportion of Western chimpanzees) could
have a slow NAT2 acetylation phenotype.
NAT genetic diversity and tests of selective neutrality
in Pan
We found that theWestern (P. t. verus) chimpanzee sub-species has the
lowest diversity among the Pan genus forNAT1 (Table 6 and Figure 2).
Indeed, expected heterozygosity (h) ranges from 0.34 inWestern chim-
panzees (BPRC sample) to 0.63 in bonobos (P. paniscus), and nucleo-
tide diversity (reported asp x 1023) from 0.58 inWestern chimpanzees
to 1.08 in Eastern (P. t. schweinfurthii) chimpanzees. A significant de-
viation from selective neutrality and demographic equilibrium due to
homozygosity excess was found for the Central (P. t. troglodytes) and
Eastern (P. t. schweinfurthii) chimpanzee sub-species with one test of
selective neutrality, i.e., the Ewens-Watterson test. However, although
highly significant, these results must be considered with caution as
they may represent artifacts due to the low sample sizes for these
two sub-species (only five and six individuals, respectively, Table 6).
No other neutrality or demographic equilibrium test returned any
significant result.
Similarly to NAT1, Western (P. t. verus) chimpanzees also have the
lowest diversity among the Pan genus for NAT2, with h varying from
0.15 inWestern (San Diego sample) to 0.38 in Central (P. t. troglodytes)
chimpanzees, and p from 0.13 inWestern to 0.50 in Central chimpan-
zees (Table 6 and Figure 2). However, in contrast toNAT1, a significant
departure from the expected diversity under selective neutrality and
demographic equilibrium was found with at least one test in all species
and sub-species before adjustment for multiple testing, with the excep-
tion of Nigeria-Cameroon (P. t. ellioti). All observed deviations were
either due to an excess of homozygosity (Western-verus, Central-
troglodytes and Eastern-schweinfurthii sub-species), and/or to an ex-
cess of rare (recent) haplotypes, yielding negative values of Tajima’sD
(BPRC sample ofWestern-verus chimpanzees, andEastern-schweinfurthii
chimpanzees) or Fu’s FS (Western chimpanzees and bonobos). For
Western chimpanzees, all three tests were significant in the BPRC
sample and Fu’s FS test remained so after correction for multiple
testing. The results were less clear-cut in the 122 sub-samples of the
San Diego sample, as deviations from neutrality were mainly observed
with Fu’s FS test (16%, 0% and 87% significant deviations with the
Ewens-Watterson, Tajima’s D and Fu’s FS tests, respectively). Sim-
ilarly to NAT1, due to small sample size, we consider with caution
the Ewens-Watterson tests results for Central (P. t. troglodytes) and
Eastern (P. t. schweinfurthii) chimpanzees (and the Tajima’s D test
result for the latter), although they were still significant after account-
ing for type I error rate. Nevertheless, taken all together, these results
suggest a possible action of directional (positive or purifying) selection
at NAT2, at least in Western (P. t. verus) chimpanzees.
At NATP, bonobos (P. paniscus) have a particularly low diversity
andWestern (P. t. verus) chimpanzees have the second lowest diversity
among the Pan genus. Indeed, expected heterozygosity ranges from
0.07 in bonobos, and 0.64 inWestern chimpanzees, to 0.89 in Central
(P. t. troglodytes) chimpanzees, and nucleotide diversity from 0.07 in
bonobos, and 0.77 in Western chimpanzees, to 2.75 in Central chim-
panzees (Table 6 and Figure 2). While the null hypothesis of selective
neutrality and demographic equilibrium was not rejected for any of
the Pan troglodytes sub-species, deviations due to a significant excessTa
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n Table 4 NAT haplotype frequencies (%) estimated in the different species and sub-species of the genus Pan and results of Hardy-
Weinberg equilibrium tests.
Pan species and sub-species
P. t. verus (Western chimpanzee)
San Diego
samplea
BPRC
sample
P. t. ellioti
(Nigeria-
Cameroon
chimpanzee)
P. t.
troglodytes
(Central
chimpanzee)
P. t.
schweinfurthii
(Eastern
chimpanzee)
P. paniscus
(Bonobo)
Pan NAT1 haplotypes
NAT1 1 79.33 (1.71) 80.43 65.00 70.00 66.70 25.00
NAT1 2 7.97 (0.94) 4.35 5.00 0 0 0
NAT1 3 1.59 (1.38) 0 0 10.00 8.33 0
NAT1 4 8.33 (0) 13.04 0 0 0 0
NAT1 5 2.78 (0) 0 0 0 0 0
NAT1 6 0 2.17 0 0 0 53.60
NAT1 7 0 0 10.00 0 0 0
NAT1 8 0 0 0 10.00 0 0
NAT1 9 0 0 0 0 8.33 0
NAT1 10 0 0 20.00 10.00 8.33 0
NAT1 11 0 0 0 0 8.33 0
NAT1 12 0 0 0 0 0 21.40
Total (2n chromosomes) 36 46 20 10 12 28
Hardy-Weinberg testb:
Ho 0.36 (0.03) 0.26 0.50 0.60 0.50 0.71
He 0.37 (0.03) 0.34 0.55 0.53 0.58 0.63
P-value 2 [0.39 ; 0.64] 0.20 0.35 . 0.99 0.51 0.45
Pan NAT2 haplotypes
NAT2 1 92.49 (1.27) 91.30 5.00 10.00 0 0
NAT2 2 2.41 (0.94) 4.35 0 0 0 0
NAT2 3 0 2.17 0 0 0 0
NAT2 4 5.10 (1.03) 0 10.00 80.00 91.70 0
NAT2 5 0 2.17 0 0 0 0
NAT2 6 0 0 85.00 10.00 0 0
NAT2 7 0 0 0 0 0 89.3
NAT2 8 0 0 0 0 0 3.57
NAT2 9 0 0 0 0 0 7.14
NAT2 10 0 0 0 0 8.33 0
Total (2n chromosomes) 36 46 20 10 12 28
Hardy-Weinberg testb:
Ho 0.15 (0.03) 0.17 0.30 0.20 0.17 0.21
He 0.15 (0.02) 0.17 0.28 0.38 0.17 0.20
P-value 2 [0.08 ; . 0.99 ] . 0.99 . 0.99 0.11 . 0.99 . 0.99
Pan NATP haplotypes
NATP 1 24.61 (2.46) 44.00 0 10.00 0 0
NATP 2 52.14 (1.7) 42.00 40.00 10.00 58.30 0
NATP 3 0 0 0 20.00 0 0
NATP 4 0 6.00 0 0 0 0
NATP 5 0 2.00 0 0 0 0
NATP 6 2.32 (1.03) 0 0 0 0 0
NATP 7 19.33 (2.21) 6.00 0 0 0 0
NATP 8 1.59 (1.38) 0 25.00 20.00 8.33 0
NATP 9 0 0 0 30.00 0 0
NATP 10 0 0 0 0 8.33 0
NATP 11 0 0 10.00 0 16.67 0
NATP 12 0 0 5.00 0 0 0
NATP 13 c 0 0 0 0 0 0
NATP 14 0 0 5.00 0 0 0
NATP 15 0 0 15.00 0 0 0
NATP 16 0 0 0 10.00 0 0
NATP 17 0 0 0 0 8.33 0
NATP 18 0 0 0 0 0 96.43
NATP 19 0 0 0 0 0 3.57
Total (2n chromosomes) 36 50 20 10 12 28
(continued)
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of homozygotes (Ewens-Watterson test) and of rare alleles (Fu’s FS test)
were found for bonobos (P. paniscus), that remained even after correc-
tion for multiple testing. Considering that the locus is a pseudogene,
its extremely low diversity in bonobos (only two NATP haplotypes
observed, one of which with a frequency over 96%, Table 4 and Figure 1)
and the associated significant results returned by the neutrality tests
are surprising and call for further investigation.
Figure 2 highlights a marked difference in diversity levels between
the threeNAT genes, particularly betweenNAT1 andNAT2. We found
only a marginally significant difference in Pan expected heterozygosity
(h) between the two functional genes,NAT1 andNAT2, after correcting
for multiple testing (P = 0.039), whereas nucleotide diversity (p) is
significantly higher at NAT1 than at NAT2 (P = 0. 0065). Since the
comparisons of the two functional paralogs with the pseudogene are
influenced by the very low diversity ofNATP in bonobos (P. paniscus),
we compared again diversity levels between genes considering only
chimpanzee sub-species. In Pan troglodytes indeed, nucleotide diver-
sity at NATP is significantly higher than at each of the two functional
genes (P = 0.018 for NAT1 vs. NATP, and P = 0.018 for NAT2 vs.
NATP, respectively), and expected heterozygosity at NATP is signif-
icantly higher than at NAT2 (P = 0.012).
Comparison of NAT genetic diversity between Pan
and humans
The total number of human haplotypes represented in the dataset
of human populations analyzed here (Supplementary Table S7) is
21 for NAT1 (3.5 per sample, on average), 44 for NAT2 (10.7), and
58 for NATP (10.6). No deviation from Hardy-Weinberg equilib-
rium was found for any of the human samples at any of the NAT
genes, after correction for multiple testing (Supplementary Table S7).
When compared to chimpanzees and bonobos, humans appear to
have about five times less diversity than Pan at the homologous NAT1
gene, while four to nine times more diversity than Pan atNAT2 (Figure
2, Table 6 and Supplementary Table S7). In Figure 2, the documented
high level of diversity of human NAT2 is clearly illustrated by its sim-
ilarity to NATP (Sabbagh et al. 2018). Both the Mann-Whitney U and
Student t-tests, adjusted for multiple testing, confirm that expected
heterozygosity and nucleotide diversity are significantly higher in Pan
species and sub-species than in human populations at NAT1, and sig-
nificantly lower at NAT2 (Supplementary Table S11). By contrast, both
expected heterozygosity and nucleotide diversity of human populations
at the NATP pseudogene fall within the range of those observed in
chimpanzees (P. troglodytes), whereas both estimates were found
to be, as expected, extremely low in bonobos. However, differences
in NATP diversity levels between humans and the Pan species and
sub-species were not significant, even before multiple testing ad-
justment, and despite the extremely low estimates of bonobos (all
P-values . 0.05).
At NAT1, while no significant rejection was observed in Pan, selec-
tive neutrality and demographic equilibrium are rejected in many hu-
man samples (Table 6 and Supplementary Table S12). Indeed, each of
the three tests of selective neutrality used rejected the null hypothesis
at NAT1 in at least one population, even after correction for multiple
testing. In the Ewens-Watterson homozygosity test, the observed ho-
mozygosity (Fo) was found always higher than the expected (Fe), and
significantly so in nine of the 19 tested population samples (eight after
correction for multiple testing). Similarly, Tajima’s D and FS values are
significantly negative in 11 (one after correction) and eight (three after
correction) population samples, respectively. Conversely, while several
tests rejected the null neutral equilibrium model at NAT2 in Pan, no
rejection was observed for this gene in human populations with any of
the three tests, after correction for multiple testing. At NATP, a single
rejection in humans was observed with Fu’s FS test after correction (in
the Dinka of Sudan, Supplementary Table S12). Thus, rejection of the
neutral equilibrium model is more consistent at NAT2 in Pan than in
humans, whereas it is more consistent atNAT1 in humans than in Pan.
Comparison with NAT genetic diversity in
other hominids
Haplotype inference for gorillas and orangutans could not be achieved
with high enough confidence, because several unknown positions in
the genotypes retrieved from GAGP overlapped with variants detected
in the sequenced samples of this study (Supplementary Tables S3, S4
and S5). Thus, only nucleotide diversity was estimated for gorillas and
orangutans (Supplementary Table S13). As shown in Supplementary
Figure S5, the relative levels of diversity at the three NAT genes differ
markedly between the two gorilla species available for this study (Western
and Eastern gorillas, G. gorilla and G. beringei, respectively), and between
the two orangutan species (Sumatran and Bornean orangutans, P. abelii
and P. pygmaeus, respectively). The results indicate a level of diversity
at NAT1 similar to that of Pan for both species of gorillas, thus also
higher than in humans, whereas the highest values among all great apes
were observed in orangutans, albeit differingmarkedly between the two
orangutan species (Supplementary File S1). At NAT2, Western gorillas
n Table 4, continued
Pan species and sub-species
P. t. verus (Western chimpanzee)
San Diego
samplea
BPRC
sample
P. t. ellioti
(Nigeria-
Cameroon
chimpanzee)
P. t.
troglodytes
(Central
chimpanzee)
P. t.
schweinfurthii
(Eastern
chimpanzee)
P. paniscus
(Bonobo)
Hardy-Weinberg testb:
Ho 0.64 (0.04) 0.60 0.90 0.60 0.67 0.07
He 0.65 (0.01) 0.64 0.78 0.89 0.67 0.07
P-value 2 [0.09 ; . 0.99 ] 0.06 0.03 d 0.15 0.76 . 0.99
a
Average over the 122 sub-samples (see text), standard deviation in brackets.
b
Test for departure from Hardy-Weinberg equilibrium; Ho: observed heterozygosity, He: expected heterozygosity (equivalent to gene diversity). The only significant
deviation from equilibrium (heterozygote excess at NATP in P. t. ellioti) is shown in bold.
c
Haplotype NATP 13, which combines SNPs at 170, 253, 289, 386, 499, 633, and 656 (Table 3), was inferred only for the genotype of the hybrid P. t. verus/
troglodytes individual.
d
P-value . 0.05 after correction for multiple testing.
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and both species of orangutans display a diversity level comparable to
that of humans, thus higher than Pan, whereas the diversity level of
Eastern gorillas is comparable to that of Pan. Finally, the highest values
of diversity among all great apes, including humans, were observed for
the two orangutan and one of the gorilla (G. gorilla) species at NATP,
while no diversity was detected in the sample of the other gorilla species
(G. beringei). These contrasting results between both the two gorilla and
the two orangutan species should however be considered with caution
in view of the extremely small sample sizes of Eastern gorillas (n = 3)
and Bornean orangutans (n = 6).
DISCUSSION
The human acetylation polymorphism, discovered in the early 1950s
and shown to be responsible for inter-individual variation in drug
biotransformation, is considered as the best-known example of a
pharmacogenetic trait (Meyer 2004; Agundez 2008a; McDonagh
et al. 2014). As reviewed in Sabbagh et al. (2018), most of its inter-
individual variation, further reflected in inter-population variation,
is due to a high number of non-synonymous polymorphisms in the
coding region of the NAT2 gene, which ranks among the most poly-
morphic human drug metabolizing genes. By contrast, human NAT1,
Figure 1 Haplotype frequency dis-
tributions at the threeNAT genes in
Pan species and sub-species.
Volume 9 July 2019 | Diversity in Hominid NAT genes | 2213
its functional paralog located some 200 Kb upstream, displays up to
13 times less diversity than NAT2 in its coding region. Several obser-
vations suggest that NAT1 and NAT2 evolved under distinct selective
regimes in humans. For human NAT1, it is generally held that its
product is functionally constrained, and thus subjected to purifying
selection, probably because of the expression of the NAT1 enzyme in
many tissues early during development (including reproductive
tissues), and its implication in the metabolism of folates (Patin et al.
2006a; Butcher and Minchin 2012). For human NAT2 however, due
to the role of its product in the detoxification of exogenous substances,
it is proposed that the mode of subsistence and/or the chemical envi-
ronment in which past populations have been living induced positive
population-specific selective pressures on the gene, thereby explaining
the documented differential distribution of acetylation prevalence
among subsistence strategies and exploited biomes (Patin et al.
2006a; Luca et al. 2008; Magalon et al. 2008; Sabbagh et al. 2008;
Mortensen et al. 2011; Podgorná et al. 2015). To gain further insights
on these evolutionary hypotheses, we performed here a comprehensive
analysis of the diversity ofNAT genes in hominids (i.e., in chimpanzees,
gorillas, orangutans, and hominins – humans, including Neanderthal
and Denisova). To the best of our knowledge, this is the first study
investigating NAT intra-species polymorphism in hominids.
Levels and patterns of diversity of the functional
arylamine N-acetyltransferase genes in the Pan genus
point to different selective pressures acting on NAT1
and NAT2
Several linesof evidence have led to the current view that, in humans, the
diversity of the NATP pseudogene can be largely ascribed to our de-
mographic history, but that ofNAT2was further shaped by population-
specific selective pressures, whereas that of NAT1 was constrained by
relatively strong purifying selection (Sabbagh et al. 2018). Indeed, a
marked geographic structure characterizes human NATP diversity,
with less diversity in populations from Europe, Asia and the Americas
than in African populations (as illustrated in Supplementary Figure S6
for the human dataset assembled in this study). For NAT2, the obser-
vations are of an excess of non-synonymous relative to synonymous
SNPs, a lack of correlation of genetic and geographic distances at the
worldwide scale, and an unusual pattern of population structure that
differentiates Asian populations from Africans and Europeans more
than expected on neutral grounds. Finally, NAT1 is much less poly-
morphic in humans, and is associated with a significant excess of
homozygotes in many populations.
In Pan, the frequency distributions of inferred haplotypes suggest
that NAT genes have evolved under different selective regimes in these
species too. Similarly to humans, these distributions are character-
ized by marked differences between the three NAT genes (Figure 1
and Table 4). At the NATP pseudogene, we found extensive variation
between Pan species and sub-species, and the shapes of these frequency
distributions resemble an expected L-shaped neutral distribution (i.e.,
a haplotype at intermediate to high frequency, other haplotypes at in-
creasingly low frequencies), except in bonobos (P. paniscus). At NAT1,
the commonest haplotype in each subspecies is more frequent than
those at NATP. The pattern is even more skewed toward a single
haplotype at very high frequency at NAT2. Moreover, while the same
NAT1 haplotype (Pan NAT11) is predominant in each chimpanzee
sub-species, at the NAT2 gene instead different haplotypes are prev-
alent in each sub-species, except for Eastern (P. t. schweinfurthii) and
Central (P. t. troglodytes) chimpanzees, which is not surprising
knowing the related demographic history of these two sub-species
(Gagneux et al. 1999; Hey 2010; Bjork et al. 2011; Prado-Martinez et al.
2013; Fünfstück et al. 2015; de Manuel et al. 2016; Lobon et al. 2016).
n Table 5 Predictions of the effect of mutations between Pan NAT1 and NAT2 coding sequences according to PolyPhen, SIFT and
PANTHER cSNP Scoring.
PolyPhen SIFT PANTHER cSNP Scoring
Haplotypes cDNA protein Scorea Predictionb Scorec Predictiond PSEPe Predictionf
Pan NAT1 (reference NAT1 1)g
NAT1 3 A789G I263M 0.279 (0.91-0.88) B 0.08 (3.08, 80) T 220 POD
NAT1 4 T597G I199M 0.369 (0.9-0.89) B 0.01 (3.07, 81) A 220 POD
NAT1 5 G76A D26N 0.377 (0.9-0.89) B 0.1 (3.08, 76) T 91 B
NAT1 7 G760C E254Q 0.892 (0.82-0.94) POD 0.07 (3.08, 80) T 455 PRD
NAT1 8 T341C I114T 0.099 (0.93-0.85) B 0.06 (3.07, 81) T 220 POD
NAT1 11 A518C E173A 0.013 (0.96-0.78) B 0.17 (3.07, 81) T 30 B
Pan NAT2 (reference NAT2 4)h
NAT2 2 C578T T193M 1 (0.00-1.00) PRD 0 (3.07, 51) A 456 PRD
NAT2 6 A514G N172D 0.001 (0.99-0.15) B 0.26 (3.07, 51) T 220 POD
NAT2 7 G145A E49K 0.002 (0.99-0.3) B 0.5 (3.07, 50) T 324 POD
NAT2 8i G191A R64Q 1.00 (0.00-1) PRD 0 (3.07, 50) A 4200 PRD
NAT2 9i A72C L24F 1 (0.00-1) PRD 0 (3.07, 50) A 4200 PRD
a
PolyPhen score: probability that a substitution is damaging; sensibility and specificity in brackets.
b
PolyPhen prediction: “benign” (B), “possibly damaging” (POD), “probably damaging” (PRD).
c
SIFT score: probability that a substitution is tolerated; median sequence information and number of sequences used for the prediction in brackets.
d
SIFT prediction: T: “tolerated” (T), A: “affect protein function” (A).
e
PANTHER cSNP Scoring PSEP (position-specific evolutionary preservation): length of time (in millions of years) of preservation of a position.
f
PANTHER cSNP Scoring prediction: “probably damaging” (PRD), “possibly damaging” (POD), “probably benign” (B).
g
The reference Pan NAT1 haplotype used is the basal haplotype in the network of NAT1 sequences (Supplementary Figure S2).
h
The reference Pan NAT2 haplotype used is the basal haplotype in the network of NAT2 sequences (Supplementary Figure S3). Since NAT2 1 differs from NAT2 4 at
a single position located 61 bp downstream the coding exon relative to the stop codon (A934G, Table 3), the two haplotypes likely translate into a similar gene
product, so that haplotypes deriving from NAT2 1 could be predicted using NAT2 4 as a reference. Instead, both haplotypes NAT2 8 and NAT2 9 derive from
NAT2 7, which differs from the basal haplotype at SNP G145A (E49K, Table 3). Thus, for the non-synonymous mutations defining NAT2 8 and NAT2 9, predictions
were performed using NAT2 7 as a reference.
i
Haplotypes NAT2 8 and NAT2 9 both bear the G145A mutation defining haplotype NAT2 7. Since the prediction tools do not allow the simultaneous specification
of two substitutions, we ran the prediction tools for G191A and A72C against NAT2 7 as a reference, instead of NAT2 4.
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In line with these observations, our analyses failed to reveal any sig-
nificant level of genetic differentiation between chimpanzee sub-species
at NAT1, while we do find significant differentiation at NAT2, except
between Eastern and Central chimpanzees (Supplementary Table S6).
At the NATP pseudogene, Western (P. t. verus) chimpanzees are sig-
nificantly differentiated from all the other P. troglodytes sub-species
(and even between the two verus samples), while no genetic differen-
tiation was found among any of the latter. Given the high levels of
Figure 2 Expected heterozygosity (h) and nucleotide diversity (p x 1023) at the three NAT genes in Pan species and sub-species (left panes) and
in human populations (right panes). The variation of values among the 122 San Diego P. t. verus sub-samples (left panes) and among human
populations samples (right panes) are shown by boxplots. The dotted lines were added to the graphs to highlight inter-locus variation. For Pan,
P-values of Wilcoxon rank-sum tests after adjustment for multiple testing (and using only the average value for the San Diego sample) were of
0.039 for NAT1 vs. NAT2, 0.065 for NAT1 vs. NATP, and 0.065 for NAT2 vs. NATP, respectively, for differences in expected heterozygosity (h),
and of 0.0065 for NAT1 vs. NAT2, 0.5887 for NAT1 vs. NATP, and 0.0974 for NAT2 vs. NATP, respectively, for differences in nucleotide
diversity (p). When restricting the tests to the chimpanzee (P. troglodytes) data only, P-values were of 0.012 for NAT1 vs. NAT2, 0.222 for NAT1
vs. NATP, and 0.012 for NAT2 vs. NATP, respectively, for expected heterozygosity, and of 0.036 for NAT1 vs. NAT2, 0.018 for NAT1 vs. NATP, and
0.018 for NAT2 vs. NATP, respectively for nucleotide diversity. For human populations, adjusted Wilcoxon rank-sum tests P-values for differences in
both expected heterozygosity and nucleotide diversity were all, 0.0001 in the comparisons ofNAT1 vs. NAT2, andNAT1 vs. NATP, and of 0.58 and
0.048 for expected heterozygosity and nucleotide diversity, respectively, in the NAT2 vs. NATP comparison.
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NATP polymorphism in chimpanzees (Figure 1 and Tables 3 and 5)
and the significant differentiation between the two verus samples,
we believe that this lack of genetic differentiation could result from
a lack of power due to the small sample sizes available for Central
(P. t. troglodytes), Eastern (P. t. schweinfurthii) and Nigeria-Cameroon
(P. t. ellioti) chimpanzees. In turn, significant differentiation levels
were estimated between bonobos and all other Pan at all three NAT
genes.
In terms of gene and molecular diversity, the different Pan species
and sub-species display a similar NAT1 - NAT2 pattern of variation,
i.e., high diversity at NAT1 and lower at NAT2, in spite of differences
in diversity levels (Figure 2). In humans instead, the NAT1 - NAT2
diversity pattern is reversed, with less diversity than Pan atNAT1 and
more at NAT2, and these differences between humans and apes are
significant (Figure 2 and Supplementary Table S11). Conversely, di-
versity was not found significantly different between humans and Pan
at NATP. A reversed pattern betweenHomo sapiens and Pan was also
highlighted by the results of the tests of selective neutrality and de-
mographic equilibrium. While at NAT1, only two rejections of the
null hypothesis (with one test only) were observed in chimpanzees
and bonobos (Table 6), deviations from expectations were found with
the three tests in several human populations (Supplementary Table
S12). At NAT2 instead, rejections were observed at least with one test
in all chimpanzees and bonobos, except in the P. t. ellioti sub-species,
while very few rejections were observed in humans (none after correc-
tion for multiple testing). Altogether, these results suggest that diversity
at NAT1 in humans could have been influenced by selective pressures
(either purifying or recent directional selection), but not in chimpan-
zees or bonobos, whereas similar selective pressures could have influ-
enced the diversity of the NAT2 gene in bonobos and at least some
chimpanzee sub-species, but not in humans.
However, it is important to consider the possible confounding effects
of population demographic history when interpreting any significant
departure of nucleotide polymorphism from equilibrium-neutral pre-
dictions. Demographic and selective events tend to leave very similar
traces over sequences. For example, a selective sweep, i.e., an episode of
recent directional selection, and a population bottleneck followed by
expansion are both expected to generate a frequency spectrum skewed
toward rare alleles. Indeed, genomic comparisons across large numbers
of individual hominids has revealed that modern humans are genet-
ically less variable than most other great apes, notably gorillas and
orangutans, and most chimpanzee subspecies, although the difference
is less pronounced when compared to Western chimpanzees, Eastern
lowland gorillas and bonobos (Gagneux et al. 1999; Kaessmann et al.
2001; Prado-Martinez et al. 2013; Xue et al. 2015). This pattern is
ascribed to the evolutionary history of our species, which is marked
by a series of recent demographic expansions, such as the one follow-
ing the founder event driving modern humans out of Africa (Li et al.
2008; Barbujani and Colonna 2010; Veeramah and Hammer 2014).
However, human and non-human hominids do not seem to differ in
the genome-wide accumulation of loss-of-function mutations and
pseudogenes, suggesting that neither human demographic expan-
sions nor the potential buffering role of human culture apparently
led to human genomes tolerating a higher mutational load (Prado-
Martinez et al. 2013). Additionally, according to (Prado-Martinez
et al. 2013), all chimpanzees and bonobos experienced a population
bottleneckmore than 2million years ago, whileWestern chimpanzees
experienced a second, more recent bottleneck some 500,000 years ago,
followed by re-expansion. Moreover, studies on the major histo-
compatibility complex (MHC) region of chimpanzees suggest that
a strong selective sweep within this region, owing to the action of a
particular viral pathogen, was likely coupled to the first bottleneck
(de Groot et al. 2002; de Groot et al. 2008), and a comparative study
of the MHC region in humans and Western chimpanzees suggests
that this first bottleneck accounts for observed differences of MHC
diversity between the two species. The lower diversity observed in
Western chimpanzees compared to the other P. troglodytes sub-species
(Figure 2 and Table 6) could indeed reflect footprints of the second,
more recent bottleneck event, thus implying that the P. t. verus sub-
species (Western chimpanzees) experienced greater genetic drift than
the others. Indeed, it is in Western chimpanzees, among all sub-species
of chimpanzees, that the lowest or one of the lowest estimations of
diversity was found, including at theNATP pseudogene, in agreement
with a well-known result at the genome level, i.e., with Central chim-
panzees being generally the more diverse and Western chimpanzees
the least (Prado-Martinez et al. 2013; Bataillon et al. 2015; de Manuel
et al. 2016). Despite these complex demographic histories, the neu-
trality tests used are known to have no statistical power to detect such
ancient demographic events (Tajima 1989b; Tajima 1989a; Simonsen
et al. 1995; Ramírez-Soriano et al. 2008). Consequently, the chimpanzee
and bonobo populations investigated can be reasonably assumed to
be at demographic equilibrium and null values of Tajima’sD and Fu’s
Fs are expected at putatively neutral genomic regions (e.g., non-genic
and intronic regions, or pseudogenes). Previous studies investigating
such regions have consistently produced null D values for Western
chimpanzees (Deinard and Kidd 1999; Kaessmann et al. 1999; Fischer
et al. 2004; Fischer et al. 2006; Fischer et al. 2011; Sugawara et al.
2011). Therefore, the significant deviations from the standard, neutral
equilibriummodel at NAT2 in chimpanzees and bonobos can be inter-
preted, in our view, as evidence for some kind of selection, most likely
purifying selection, which is how such patterns are interpreted for
NAT1 in humans (Sabbagh et al. 2018).
On the other hand, the few rejections of the null hypothesis at
NAT1 in Pan rather support a lack of selective pressure at this gene,
but this conclusion fails to explain the lack of NAT1 genetic differ-
entiation among chimpanzees, with the same predominant haplo-
type in all P. troglodytes (i.e., NAT11), as opposed to the patterns
characterizing NAT2 and NATP. In view of the observed similar
level of diversity between humans and chimpanzees at the NATP
pseudogene, the differences found between the two functional NAT
paralogs, both among Pan, and between Pan and humans rather
argue for some contribution of selective pressures acting on both
these genes. Neither the diversity indices that we estimated nor the
selective neutrality tests that we performed account for differences
in the functional impact of mutations. Considering such functional
effects could help to identify the kind of selective pressures at work,
and their likely magnitude.
At the NAT1 gene, haplotype NAT11 is the most frequent in all
chimpanzee sub-species, whereas it is NAT16 in bonobos (Figure 1).
These two haplotypes are nevertheless likely to confer a similar enzy-
matic profile since they only differ by a synonymous SNP (T369C,
Table 3). Therefore, it is expected that a majority of chimpanzees and
bonobos have a similar NAT1 acetylation capacity. Moreover, at each
of the NAT1 positions that are polymorphic in Pan, all other great
apes, including humans are apparently fixed on the nucleotides of
the major Pan haplotype NAT11. Thus, the maintenance of NAT11
for approximately half a million years (TMRCA of Pan troglodytes)
and of a likely similar acetylation capacity (NAT16 differs from
NAT11 by a single synonymous substitution) for about 2 million
years (TMRCA of Pan) points to the effect of purifying selection acting
on this gene to preserve such acetylation capacity. At NAT2, as
already stated, frequency distributions in Pan were found to differ
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markedly from those atNAT1, not only because they are more skewed
toward a high frequency of the major haplotype, but also because
this prevalent haplotype is different between sub-species. Pan NAT2
is also characterized by a low level of diversity compared to NAT1
and NATP, and to human NAT2 as well (Figure 2). Theoretically,
such pattern could be due either to rapid genetic drift in populations
of chimpanzees and bonobos, or to directional selection, possibly pu-
rifying selection, acting to preserve specific haplotypes, depending on
the sub-species. Both hypotheses are supported by the tests of selective
neutrality and demographic equilibrium, which revealed several rejec-
tions in favor of directional selection or a population expansion after a
bottleneck. Moreover, if only polymorphic positions within the Pan
coding exon are considered (Table 3 and Supplementary Figure S2),
only three mainNAT2 haplotypes are observed, i.e.,NAT21/NAT24
(most frequent in P. t. verus, P. t. troglodytes and P. t. schweinfurthii),
NAT26 (P. t. ellioti), and NAT27 (P. paniscus). Thus, although hap-
lotype variation between chimpanzee sub-species is apparently higher
at NAT2 than at NAT1, it is likely that the evolution of NAT2 in Pan
is nevertheless functionally constrained. This idea finds support in the
comparison of NAT2 with the highly variable NATP pseudogene. In
spite of this, similarly to observations in humans (Patin et al. 2006a;
Mortensen et al. 2011), significant linkage disequilibrium among the
three NAT gene family members is mainly detected between NAT2
and NATP (Supplementary Table S14, tested only in Western chim-
panzees). It is thus reasonable to assume that the pseudogene has
been more free to accumulate recent mutations, while selection acts
to remove harmful mutations in NAT2. In this context, the extremely
low NATP diversity in bonobos is intriguing, the more so as their
diversity pattern at NAT1 and NAT2 is similar to that of chimpanzees
(Figure 2). We verified that this depleted polymorphism in the pseu-
dogene could not be ascribed to a lower quality of the SNP calling
process or lower coverage for bonobos in the GAGP data. Note that
in the GAGP whole genome study, bonobos and also Eastern gorillas
(G. beringei) showed the lowest genetic diversity among all great apes,
and displayed distributions of homozygosity tracts similar to those
of human populations having experienced strong genetic bottlenecks
(Prado-Martinez et al. 2013; Xue et al. 2015).
Prediction of the existence of different profiles of
acetylation in chimpanzees and bonobos
In humans, polymorphisms identified in NAT1 and NAT2 led to the
definition of haplotypes with a known acetylation profile when an
association between a mutation and the functionality of the protein
was observed in vivo or in vitro (Walraven et al. 2008; Zhu and Hein
2008; Zhu et al. 2011). In other primates, for the time being, func-
tional knowledge only exists for the rhesus macaque NAT2 gene.
Indeed, a recent study (Tsirka et al. 2014) demonstrated that the
function of the NAT2 enzyme in the human and rhesus macaque
species diverges in substrate selectivity, shifting substrate affinity of
the enzyme between bulkier NAT2 substrates and smaller NAT1
substrates, and that this shift is due to a single substitution, that does
not otherwise alter the stability and the overall activity of the protein.
Such knowledge does not exist yet for chimpanzees, and we thus used
three in silico tools to predict the potential consequence of a substitu-
tion on the function of Pan NAT proteins (Table 5).
We therefore suggest that, compared to the Pan basal haplotype
NAT11, nine derived haplotypes might translate into an equivalent
phenotype, whereas two might have a moderate damaging effect.
Indeed, none of the SNPs detected in NAT1 have been predicted as
damaging by the three tools concomitantly, but the comparison of
our results for Pan haplotypes with the outcomes of predictions for
human haplotypes with known effects raises the possibility that
two Pan NAT1 haplotypes, NAT14 and NAT17, could have a
moderate “slowing” effect on enzymatic activity (similar to that of
human haplotype NAT114B, when considering the similarity of the
results outputted by the prediction tools).
At the NAT2 gene, non-synonymous mutations defining three Pan
derived haplotypes, NAT22, NAT28, and NAT29, were predicted as
damaging, with good confidence by the three tools. A slower enzymatic
activity associatedwith these haplotypes could thus be expected. Two of
these three haplotypes are rather uncommon, each being observed at a
frequency below 5% in one species only:NAT22 inWestern chimpan-
zees (P. t. verus) and NAT28 in bonobos (P. paniscus) (Table 4, Figure
1, Supplementary Table S4, and Supplementary Figure S3). Haplotype
NAT29 was also detected in bonobos only, but it has an estimated
frequency over 7%. Hence the cumulated frequencies of NAT2 hap-
lotypes potentially conferring slower NAT2 enzymatic activity in
P. paniscus could reach 10%. This translates into an expected fre-
quency of carriers of two potentially slow haplotypes of 1%, vs. 18%
of heterozygous slow/rapid carriers (observed frequencies were of
0% and 21.4%, respectively). By comparison, the lowest frequen-
cies of NAT2 slow acetylators in human populations (either directly
documented by phenotypic studies, or indirectly estimated by the
proportion of carriers of two slow haplotypes) vary by around 10%
(Sabbagh et al. 2011). Such low frequencies are encountered both
in hunter-gatherer populations around the world (with the lowest
values among some hunter-gatherer populations of the American
continent (Fuselli et al. 2007), and in some North East Asian popu-
lations (in China, Korea and Japan). For the Pan species, we tenta-
tively speculate that two additional haplotypes (NAT26 andNAT27)
could be associated with a substrate-dependent reduction in acetyla-
tion activity, given the similarity of results returned by the prediction
tools with those of human haplotypes for which such substrate-
dependent activity has been proposed (i.e., humanNAT27A,NAT27B,
and NAT210, Supplementary File S1 and Supplementary Table S15).
Although we acknowledge that such assertion is based on very lim-
ited evidence, it nevertheless opens up the possibility that, compared
to chimpanzees, NAT2 activity in bonobos could be globally reduced
given that NAT27 is the most prevalent haplotype in this species
(Figure 1 and Supplementary Figure S3).
In summary, in the present state of knowledge, our results sug-
gest the existence among chimpanzees and bonobos, as in humans, of
diversified acetylation profiles for bothNAT1 andNAT2 genes. While
for NAT1 only two infrequent Pan haplotypes might confer a slower
enzymatic activity than the reference, for NAT2, two of the three
haplotypes observed in bonobos are predicted to do so, as well as
one in chimpanzees. In terms of frequencies, however, the majority
of NAT2 haplotypes observed in chimpanzees are likely associated
with a “normal” acetylation capacity that would be the Pan equivalent
corresponding to human rapid acetylation (Supplementary File S1
and Supplementary Table S16). It is thus likely that, in chimpanzees,
mutations modifying the functionality of the NAT1 and NAT2 en-
zymes in a fashion that slows acetylation could be subject to purifying
selection. Purifying selection acting on the chimpanzee NAT2 gene is
consistent with its low diversity within sub-species as compared to
NATP, and its high molecular differentiation among Pan sub-species.
However, the greater molecular diversity found at NAT1 within
sub-species is more compatible with a mechanism of (weak) positive
directional selection favoring the prevalent P. troglodytes NAT11
haplotype in all sub-species. Although constrained by the sample
sizes available, our results raise the possibility that in bonobos, how-
ever, functional constraints at NAT2 against slower acetylation could
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be less stringent than in chimpanzees, allowing a predicted frequency
of NAT2 slow acetylation haplotypes of 10% in this species.
These evolutionary hypotheses need to be tested with functional
studies of the in vitro and/or in vivo activities of NAT1 and NAT2
enzymes in Pan species. Moreover, such hypotheses will also need to
address further complexities, such as the NAT2 metabolic adapta-
tions (i.e., shifts in NAT2 enzymatic activity) recently reported in a
study comparing a local human population with a population of
first-generation emigrants (Aklillu et al. 2018). Finally, we acknowl-
edge that our analyses are based on only a few segregating sites, which
is expected given the short length of the NATs open-reading frames.
Hence larger sample sizes than the ones available in this study are
required to make robust assertions on the prevalence of distinct ace-
tylator profiles, and to confirm the patterns of molecular diversity of
NAT genes found in chimpanzees and bonobos.
Divergent selective pressures acting on the evolution of
NAT genes in humans and chimpanzees
The results of the three tests of selective neutrality used on the human
dataset analyzed here support the current view that human NAT1 di-
versity is constrained by purifying selection (Table 6 and Supplemen-
tary Table S12). On the other hand, the finding of higher frequencies
of human NAT2 slow acetylator phenotypes in food-producing pop-
ulations compared to hunter-gatherers supports the idea that the gene
was impacted by selective pressures induced by the modes of subsis-
tence adopted by past populations, and in particular their diets (Patin
et al. 2006a; Luca et al. 2008; Magalon et al. 2008; Sabbagh et al. 2008;
Mortensen et al. 2011; Podgorná et al. 2015). However, this selective
hypothesis fails to be consistently supported, with tests of selective
neutrality on human NAT2 variation producing very few significant
results (including those from this study, although see (Patillon et al.
2014)). Several explanations for the observed weak and inconstant
signals of selection have been suggested, such as the action of adap-
tive mechanisms difficult to detect through the standard frequency
spectrum tests that we and others have used (i.e., selection on standing
variation, selection favoring heterozygotes carrying a slow and a rapid
haplotype, ancient balancing selection masked by directional selection
on specific haplotypes, or recent relaxation of functional constraints).
Moreover, consistent evidence for genetic and genomic signatures
of demographic expansions in humans in the past (Li et al. 2008;
Barbujani and Colonna 2010; Veeramah and Hammer 2014) could
have mitigated molecular signals of selective mechanisms such as
balancing selection and/or selection on standing variation. Interest-
ingly, in human populations from the African Sahel and surround-
ing regions, higher proportions of NAT2 rapid acetylators were found
not only among hunter-gatherers, as opposed to food-producers,
but also among populations living in humid tropical environments,
as opposed to those living in more arid zones, independently of their
mode of subsistence. It thus raises the possibility that selective pres-
sures on NAT2 could be exerted not only by shifts to new dietary
habits, but by the natural chemical environment as well (Podgorná
et al. 2015).
Our results suggest that the diversity of NAT genes in chimpanzees
could result from evolutionary forces that differ from those operating
in humans. Today, chimpanzees live mainly in humid tropical envi-
ronments (according to the classification of the United Nations Envi-
ronment Program) even if the limits of their habitat are also located in
more arid zones (such as in Senegal, Guinea,Mali, Ivory Coast, Uganda,
Tanzania and the Republic of Congo). Besides the differences in the
overall efficiency of purifying and positive selection acting on the
genomes of great ape species, which was shown to be correlated with
their long-term population sizes (Cagan et al. 2016), differences in
intensity of selective pressures exerted by the environment could also
be invoked. Chimpanzees and bonobos are raw food “hunter-gatherers”
that feed mainly on plant matter, but also eat uncooked insects, birds,
eggs and small- to middle-sized mammals. Moreover, it is generally
assumed that chimpanzee and bonobo diets have not substantially
changed over time, in contrast to humans, whose diets have done so,
probably several times, over the last 200 thousand years.
In humans, besides their influence on the effectiveness of prescribed
medications, polymorphisms at NAT2, and also at NAT1, have been
associated with differential susceptibility to various cancers linked to
arylamine exposure (Hein 2002; Agundez 2008b; Ladero 2008; Selinski
et al. 2015; Hein 2018; Laurieri et al. 2018). Such exposures occur with
cigarette smoke, gases and pollutants produced by various chemical
industries, as well as diets including meat or fish cooked (or fried) at
high temperatures (Weisburger 2002; Chung 2015; Fahrer 2016). Patin
et al. (2006a) stressed the idea that changes in exposure to xenobiotics
with carcinogenic risk or other toxicities associated with the new diets
introduced by the transition to food-producing life-styles, as opposed
to hunter-gatherer subsistence modes, might have led to changes in the
selective pressures acting on drug-metabolizing enzymes such as the
NAT enzymes. Here we speculate that the entire phenomenon of food
processing, which is intimately linked to the handling of fire, and thus
represents a major distinctive human feature common to all modes of
subsistence, may have exposed our species to new, food-borne carcin-
ogens and other toxic molecules seldom encountered in the diets of
other primate species. Human biological adaptation stemming from
the controlled use of fire is an idea that runs back at least to Charles
Darwin (Wrangham and Carmody 2010). It is supported, notably, by
studies on the influences of a cooked diet on gene expression in the liver
(Carmody et al. 2016), and the hypothesis of a specific genetic adapta-
tion to fire use is advocated to explain the fixation, in modern humans,
of a single nucleotide substitution in the aryl hydrocarbon receptor
(AHR) gene, which results in a lowered sensitivity of the receptor to
toxic exogenous AHR-ligands, such as polycyclic aromatic hydrocar-
bons (PAHs) that are contained in fire smoke and cooked and smoked
foods (Hubbard et al. 2016).
Turning back to chimpanzees, we could thus speculate that living
in a more limited environment and having experienced little changes
in diet, selective pressures such as those affecting humans have been
less intense or even non-existent. Instead, the hypothesis of purifying
selection acting tomaintain an acetylation activity sufficiently adapted
to the chimpanzees’ environment and diet is consistent with their low
diversity atNAT2, the significant rejections of neutrality for this gene,
at least for Western chimpanzees, and the low frequencies of those
mutations that were predicted to be damaging. While NAT2 muta-
tions leading to a slower acetylation phenotype are hypothesized to
have recently become advantageous in many human populations as
they settled in new environments and/or adopted new subsistence
strategies, including the consumption of cooked and roasted foods,
such mutations are likely to have been deleterious in chimpanzees,
and thus negatively selected.
Although it is likely that chimpanzees and bonobos did not
experience similar shifts in diets as humans did, the hypothesis of
a less stable chemical environment for humans than for other great
apes is challenged by major climatic changes, such as the drier condi-
tions developing in the Last Glacial Maximum which have been pro-
posed to be associated with the speciation process leading to Eastern
andWestern gorillas, and the demographic decline of the latter species
(Roy et al. 2014; Xue et al. 2015). Moreover, our analyses did not pro-
duce systematically matching results between Western chimpanzees
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and the other sub-species, in particular with regards to the selective
neutrality tests. A priori, these discrepancies could result from the
smaller sample sizes of Central, Eastern and Nigeria-Cameroon
chimpanzees, making miss-estimation of haplotype frequencies a
possible issue. Note that the sample sizes of Western chimpanzees
(18 and 23 individuals for San Diego and BPRC, respectively, Table 4)
are smaller than the average those of the human populations samples
analyzed here (between 60 and 70 individuals, Supplementary Table S7),
although several human samples from African populations are rep-
resented by less than 20 individuals. Moreover, one cannot exclude
the possibility of sequencing errors, particularly for those haplotypes
defined by singleton SNPs and observed only once (e.g., Eastern
chimpanzee Andromeda, whose data were retrieved from the GAGP,
is the only carrier of NAT210). Finally, sub-species determination,
very often exclusively based on mitochondrial DNA, could be erro-
neous, especially so in the presence of hybrids (Becquet et al. 2007);
see also Supplementary File S1).
Sample sizes at least comparable to those ofWestern chimpanzees in
the present study are thus needed to confirm the apparent differences
between sub-species that we detected. The recent publication of new
genomes for these sub-species (de Manuel et al. 2016) is likely to allow
an evaluation of our findings in the near future. These findings also call
for studies on chimpanzees living in different environments and under
different chemical exposure. For instance, numerous Eastern chimpan-
zees of the Sebitoli community present congenital anomalies as well
as palate clefts (Krief et al. 2014; Krief et al. 2015; Krief et al. 2017). In
humans, deficiency in folates, in which NAT1 is implicated, is often
associated with many congenital malformations including palate clefts
(Wahl et al. 2015), and some mutations in both NAT1 and NAT2 have
been associated with this condition (Song et al. 2013; Santos et al. 2015).
A hypothetical shift in function between NAT1 and
NAT2 during hominid evolution
The differences in diversity levels between NAT1 and NAT2 among
great ape species suggest that, as in humans, a differentiated function
for the two enzymes exists also in other hominid species. In humans,
the NAT1 and NAT2 isoenzymes have a different expression profile
and acetylate different substrates (Jensen et al. 2006; Wakefield et al.
2007; Butcher and Minchin 2012; Laurieri et al. 2014; Sim et al. 2014).
Human NAT1 is expressed in most tissues from very early during
development and is assumed to play a role in the metabolism of
folates, while NAT2 is mostly expressed in the liver and intestines
and its substrates are not supposed to influence its regulation, con-
trarily to NAT1. As reviewed by (Butcher and Minchin 2012), the
transcriptional and post-transcriptional regulation of the NAT1 en-
zyme could also have a higher effect on NAT1 activity than the ge-
notype, contrarily to what is known for NAT2. Notably, it is suggested
that epigenetic regulation depending on the concentration of some
substrates could affect the activity of NAT1 in cells (Wakefield et al.
2010). If differences in diversity levels between the two genes are
linked to differences in factors contributing to the inter-individual
variation in enzymatic activity between NAT1 (high variation in ex-
pression regulation) and NAT2 (high variation in protein sequence)
is an open question. It would be tempting to assume that the function
of the two enzymes is different in chimpanzees, compared to humans,
in view of the reversed NAT1-NAT2 diversity pattern of chimpanzees
and other great ape species (bonobos and Sumatran orangutans).
For instance, one could consider the possibility of a shift in sub-
strate affinity between the two isoenzymes during hominid evo-
lution, as suggested by the expression study of the rhesus macaque
NAT2 gene (Tsirka et al. 2014), leading to a divergence in function
between Pan and Homo. At present, however, neither temporal (i.e.,
early or later in development), nor spatial (e.g., ubiquitous vs. tissue-
specific) differences in expression of the two NAT isoenzymes
are known in other great ape species besides humans, so we can
only speculate on possible environmental factors that could exert a
selective pressure on NAT genes in our closer relatives.
In conclusion, we have found high levels of diversity of NAT genes
in chimpanzees and bonobos, which is similar to humans. However
the diversity is reversely distributed in chimpanzees and bonobos, such
that there is higher diversity in Pan NAT1 and lower diversity in Pan
NAT2, whereas the opposite is observed in humans. A reversed pattern
between Pan and humans was also returned by the tests of selec-
tive neutrality and demographic equilibrium. Rejections of the model
in chimpanzees were found mostly associated with NAT2, and likely
due to directional selection, whereas in human populations this ap-
pears to be the case for NAT1, thus suggesting distinct selective pres-
sures acting on Pan NAT1 and NAT2 compared to humans. Our
analyses of the predicted functional impact of mutations detected
in non-human primates suggest that a non-negligible proportion
of chimpanzees could have a moderately reduced NAT1 acetylation
capacity, in sharp contrast with most human populations. In turn,
reduced NAT2 acetylation capacity is known to be frequent in many
human populations, and our analyses predicted that this could also
be the case for a significant proportion of bonobos, but less so of
chimpanzees. Altogether, our results raise the possibility that humans
and chimpanzees evolved some divergence in functionality at the NAT
genes in the course of hominid history, such as divergence in substrate
affinity/specificity/selectivity for each of the two enzymes. Such hypo-
thetical shift in function could be due to fixed substitutions between
humans and Pan NAT genes, as has been shown for macaques com-
pared to humans. On the basis of the known role of NAT2 in the
metabolism of smoke-contained aromatic amines, we postulate that a
functional divergence of NATs between Pan and humans could have
been driven by the development of fire handling and food processing in
humans, a hypothesis that could be addressed in the future by func-
tional studies of NAT1 and NAT2 enzymatic activities in great apes.
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